clinical trial · NCT05989711
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
Non-Alcoholic Steatohepatitis (NASH)PemvidutidePlacebo
brief summary
Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
started
Jul 27, 2023
primary completion
Apr 29, 2025
completion
Nov 25, 2025
last updated
Dec 26, 2025
detailed description
A Phase 2, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in NASH.
official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol